Elsevier

Brain, Behavior, and Immunity

Volume 61, March 2017, Pages 117-126
Brain, Behavior, and Immunity

Full-length Article
Reparative effects of interleukin-1 receptor antagonist in young and aged/co-morbid rodents after cerebral ischemia

https://doi.org/10.1016/j.bbi.2016.11.013Get rights and content
Under a Creative Commons license
open access

Highlights

  • IL-1β is a key proinflammatory cytokine involved in ischemic brain damage.

  • Administration of IL-1Ra improves the stroke outcome in young and co-morbid rats.

  • Acute IL-1Ra administration also promotes neurogenesis after experimental stroke.

Abstract

Neuroprotective strategies for ischemic stroke have failed to translate from bench to bedside, possibly due to the lack of consideration of key clinical co-morbidities. Stroke and co-morbidities are associated with raised levels of the pro-inflammatory cytokine interleukin-1 (IL-1). Inhibition of IL-1 by the administration of interleukin-1 receptor antagonist (IL-1Ra) has shown to be neuroprotective after experimental cerebral ischemia. Stroke can also trigger a robust neuroreparative response following injury, yet many of these new born neurons fail to survive or integrate into pre-existing circuits. Thus, we explore here effects of IL-1Ra on post-stroke neurogenesis in young and aged/co-morbid rats. Aged lean, aged Corpulent (a model of atherosclerosis, obesity and insulin resistance) and young Wistar male rats were exposed to transient cerebral ischemia, received subcutaneous IL-1Ra 3 and 6 h during reperfusion, and effects on stroke outcome and neurogenesis were analyzed. Our results show that administration of IL-1Ra improves stroke outcome in both young and aged/co-morbid rats. Furthermore, IL-1Ra not only increases stem cell proliferation, but also significantly enhances neuroblast migration and the number of newly born neurons after cerebral ischemia. Overall, our data demonstrate that systemic administration of IL-1Ra improves outcome and promotes neurogenesis after experimental stroke, further highlighting the therapeutic potential of this clinically approved drug.

Keywords

Cerebral ischemia
Interleukin-1 receptor antagonist
Neuroprotection
Neurogenesis
Co-morbidity
Risk factors

Cited by (0)

1

Both authors have contributed equally to this work.